Consensus CT delineation guidelines for head and neck organs at risk from eight cooperative groups, with anatomical descriptions and example images. Citation checked against Crossref; content not yet reviewed by DoseLab.
Globes (Eyes)
Dose constraints
Head & Neck Planning Essentials
| Schedule | Constraint | Source |
|---|---|---|
| Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤35 Gy, max ≤50 Gy | RTOG 0615 |
| Anterior globe (cornea, lens, iris): max ≤30 Gy; PRV max ≤35 Gy | DAHANCA 2025 |
Quoted from eviQ 5049, checked 2026-09-24. Full table with references →
Anatomy
The eyeballs, each sitting in its bony orbit, with the lens and cornea at the front and the retina lining the back.
Function in the body
The eyes focus light onto the retina at the back of the eye, which turns it into nerve signals for the brain.
Why it matters
High dose to the back of the eye can damage the retina and cause vision loss; dose to the front can cause dry eye, corneal injury and cataract. The globes matter when the target reaches the nasal cavity, sinuses, orbit or skull base — mainly nasopharynx and sinonasal cancers. In brain radiosurgery and glioma treatment they matter for targets near the orbit and the frontal lobe.
How to contour
Brouwer 2015 splits each eyeball into two structures rather than one whole globe:
- Anterior segment: everything in front of the vitreous — the cornea, iris, ciliary body and lens.
- Posterior segment: everything behind the lens — the vitreous, retina and choroid. It includes the whole retina but excludes the optic nerve.
The EPTN 2018 atlas instead contours the cornea and the retina as thin separate structures (drawn with a 2–3 mm brush). Many protocols evaluate the whole globe, so check which structure your limit refers to. The lens is contoured as its own structure.
The European Particle Therapy Network contouring atlas for brain organs at risk on CT and MRI, with anatomical descriptions and boundaries. Citation checked against Crossref.
Further reading
- RTOG 0615 — RTOG 0615 protocol — A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer Source
- DAHANCA 2025 — Danish Head and Neck Cancer Group (DAHANCA) Radiotherapy Quality Assurance Guidelines 2025 Source